Tyra Biosciences (TYRA) Projected to Post Earnings on Wednesday

Tyra Biosciences (NASDAQ:TYRA) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.6687) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts expect Tyra Biosciences to post ($2.68) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $21.52 on Wednesday. The company has a market capitalization of $1.28 billion, a P/E ratio of -8.97 and a beta of 0.75. The company’s 50-day simple moving average is $22.96 and its two-hundred day simple moving average is $29.94. Tyra Biosciences has a one year low of $13.35 and a one year high of $40.65.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $53.00 target price on shares of Tyra Biosciences in a research report on Thursday, September 10th. Jefferies Financial Group restated a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. HC Wainwright cut their target price on Tyra Biosciences from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, September 22nd. Oppenheimer reissued an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. Finally, William Blair raised shares of Tyra Biosciences to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $47.20.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for patients with cancer and other diseases driven by fibroblast growth factor receptor (FGFR) abnormalities. The company uses its proprietary SNÅP platform to discover and design small-molecule therapies intended to selectively target FGFR alterations while addressing mechanisms of treatment resistance.

Tyra’s lead program, TYRA-300, is an oral, selective FGFR3 inhibitor being evaluated in clinical studies for FGFR3-altered urothelial cancer and other potential indications.